LivaNova PLC reported robust financial results for the third quarter ended September 30, 2024, with total net revenue increasing 11.2% to $318.1 million compared to $286.1 million in the third quarter of 2023. Excluding the ACS segment wind-down, revenue grew 12.3% on a constant-currency basis. Adjusted diluted earnings per share reached $0.90, up from $0.73 in the prior-year quarter.
The Cardiopulmonary segment was a significant growth engine, with revenue increasing 15.6% to $172.2 million, fueled by Essenz Perfusion System sales and strong consumables demand. Neuromodulation revenue also grew 8.5% to $139.9 million, with strength in the U.S. and Rest of World regions.
The company raised its full-year 2024 revenue guidance to 8.5% to 9.5% growth on a constant-currency basis, or 10% to 11% excluding the ACS segment wind-down. Adjusted diluted earnings per share for 2024 are now expected to be between $3.30 and $3.40, reflecting strong operational execution and an improved business outlook.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.